Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Julphar
Farmers Insurance
McKesson
Merck
US Department of Justice
Teva
Healthtrust
Fish and Richardson
Harvard Business School

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,796,276

« Back to Dashboard

Summary for Patent: 8,796,276
Title:Heterocyclic compounds for the treatment of neurological and psychological disorders
Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. ##STR00001##
Inventor(s): Remenar; Julius F. (Framingham, MA), Blumberg; Laura Cook (Lincoln, MA), Zeidan; Tarek A. (Watertown, MA)
Assignee: Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:13/607,066
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,796,276

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-001 Oct 5, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-002 Oct 5, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-003 Oct 5, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-004 Jun 5, 2017 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,796,276

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,431,576 Heterocyclic compounds for the treatment of neurological and psychological disorders ➤ Subscribe
8,686,009 Prodrugs of NH-acidic compounds ➤ Subscribe
9,102,618 Prodrugs of NH-acidic compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,796,276

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 6093341 ➤ Subscribe
Japan 2015071641 ➤ Subscribe
Japan 2016172742 ➤ Subscribe
Saudi Arabia 3937 ➤ Subscribe
Portugal 2445502 ➤ Subscribe
Poland 2445502 ➤ Subscribe
New Zealand 597108 ➤ Subscribe
New Zealand 597107 ➤ Subscribe
Lithuania 2445502 ➤ Subscribe
Japan 2017048247 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Federal Trade Commission
US Army
McKinsey
Novartis
Fish and Richardson
Dow
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot